A study of the safety and tolerability of AZD5213 effect on sleep for patients with Alzheimer's/Cognitive Impairment

Exclusion Criteria

• - Significant neurological disease or dementia other than AD or MCI.
• - Current episode or symptoms of major depressive disorder or other major psychiatric disorder.
• - History of self-reported sleep duration of less than 4 hours per night or less than 4 hours average total sleep time per night during Baseline PSG assessment.
• - History or present symptoms of a sleeping disorder such as sleep apnea.
• - History of cancer in the last 5 years.
• - Use of anti-AD drugs (including off-label drugs and herbal medications) with the exception of donepezil, memantine, and/or rivastigmine transdermal system, as monotherapy or in combination in the following conditions: treatment with donepezil (5 mg to 10 mg daily), memantine, and/or rivastigmine transdermal system or combination regimens for at least 3 months and a stable dose(s) for the last 2 months prior to randomization is allowed.